immune response modifier (SDP Oncology)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameimmune response modifier (SDP Oncology)
Drug Alias Nameimmune response modifier (Boston Biomedical)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoston Biomedical Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoston Biomedical IncSumitomo Pharma Oncology Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A